NASDAQ
16.39USD
+0.70 (+4.46%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.9B
P/E
—
EPS
—
Beta
0.98
52W range
9.82-21.451
Day range
15.77–16.42
Open
15.99
Prev close
15.69
Volume
1.5M
Avg volume
1.4M
Dividend
0.00
IPO
2015-10-02
https://seekingalpha.com/article/4925410-novocure-why-im-fading-the-q2-earnings-rally · 7/24/2026+0.10
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-celsius-holdings-inc---celh-302822350.html · 7/9/2026-0.80
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novocure-limited---nvcr-302822349.html · 7/9/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-primoris-services-corporation---prim-302811269.html · 6/25/2026-0.50
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novocure-limited---nvcr-302811265.html · 6/25/2026-1.00
https://www.prnewswire.com/news-releases/accenture-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-accenture-acn-302804925.html · 6/19/2026-0.80
https://www.prnewswire.com/news-releases/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr-302804902.html · 6/19/2026-1.00
https://www.defenseworld.net/2026/04/04/jpmorgan-chase-co-buys-144024-shares-of-novocure-limited-nvcr.html · 4/4/2026+0.30
https://www.defenseworld.net/2026/04/04/sg-americas-securities-llc-grows-stake-in-ultra-clean-holdings-inc-uctt.html · 4/4/2026+0.40
https://www.investors.com/stock-lists/sector-leaders/globus-medical-gmed-stock-preliminary-results/ · 1/16/2026+0.60
https://seekingalpha.com/article/4856762-novocure-2026-pipeline-outlook-make-this-stock-a-speculative-buy · 1/2/2026-0.20
https://www.prnewswire.com/news-releases/pancreatic-cancer-market-set-to-expand-during-the-forecast-period-20252034-as-precision-medicine-and-immunotherapy-transform-treatment-landscape--delveinsight-302637673.html · 12/10/2025+0.40
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
